Stocktoria
BIOCRYST PHARMACEUTICALS INC BCRX
BIOCRYST PHARMACEUTICALS INC (BCRX) earns a Piotroski F-score of 6/9 (mixed financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $874.8M at a 30.2% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -2.27 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Recent analyst actions
| Date | Firm | Rating |
|---|---|---|
| 2026-06-30 | HC Wainwright & Co. | Buy (main) |
| 2026-06-30 | Cantor Fitzgerald | Overweight (main) |
| 2026-05-07 | Citizens | Market Outperform (main) |
| 2026-05-07 | Wedbush | Outperform (main) |
| 2026-05-06 | Needham | Buy (main) |
| 2026-01-30 | RBC Capital | Outperform (main) |
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 6/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.405 |
| Retained earnings / assets | -2.929 |
| EBIT / assets | 0.663 |
| Equity / liabilities | -0.188 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| BCRX | BIOCRYST PHARMACEUTICALS INC | 6/9 | -2.63 | 9.6 | +94.1% |
| RGEN | REPLIGEN CORP | 6/9 | 5.48 | 169.6 | +16.4% |
| NVAX | NOVAVAX INC | 4/9 | -7.28 | 3.3 | +64.7% |
| TECH | BIO-TECHNE Corp | 5/9 | 5.89 | 151.4 | +5.2% |
| ADMA | ADMA BIOLOGICS, INC. | 5/9 | 8.8 | 13.8 | +19.6% |
| TARS | Tarsus Pharmaceuticals, Inc. | 4/9 | 2.84 | — | +146.7% |
| IMCR | Immunocore Holdings plc | 3/9 | 2.37 | — | +29% |
About BIOCRYST PHARMACEUTICALS INC
BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated and seasonal influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat HAE. It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in phase 1; Avoralstat, an ocular plasma kallikrein inhibitor for diabetic macular edema that is in Phase 1; Navenibart, a monoclonal antibody plasma kallikrein inhibitor for HAE which is in Phase 3; BCX17725, an investigational protein therapeutic KLK5 inhibitor for the treatment of netherton syndrome that is in phase 1 clinical trial; STAR-0310, a monoclonal antibody OX40 antagonist for the treatment of atopic dermatitis which is in Phase 1a trial. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., and Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
FAQ
Is BCRX financially healthy?
BIOCRYST PHARMACEUTICALS INC's Piotroski F-score is 6/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does BCRX pay a dividend?
No, BIOCRYST PHARMACEUTICALS INC does not currently pay a dividend.
How profitable is BCRX?
In FY2025, BIOCRYST PHARMACEUTICALS INC had a net margin of 30.2%.
What is BCRX's P/E ratio?
BIOCRYST PHARMACEUTICALS INC's trailing price-to-earnings (P/E) ratio is about 9.6×, based on its latest annual earnings.
What is the analyst price target for BCRX?
The average Wall-Street price target for BIOCRYST PHARMACEUTICALS INC is $21.80, about 105.9% above the recent price, from 10 analysts (consensus: strong buy).
Is BCRX a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on BIOCRYST PHARMACEUTICALS INC: a Piotroski F-score of 6/9, an Altman Z″ in the distress zone, a P/E of about 9.6×. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.